H.C. Wainwright initiates coverage of Lakewood-Amedex Biotherapeutics with buy rating and $3 target
LABT•H.C. Wainwright initiated coverage of Lakewood-Amedex Biotherapeutics with a buy rating and a $3 target price.
Related News
Hubbell: Bernstein cuts target price to $560 from $584
HUBB•
Etsy CFO Lanny Baker steps down effective March 1, 2027
ETSY•
Hayward Holdings Q3 sales beat estimates on higher volumes
HAYW•
GE Vernova Q3 revenue $12.6 billion vs. IBES estimate of $11.991 billion
GEV•
Extreme Networks Q1 revenue beats estimates on Platform ONE demand
EXTR•